Eminence Capital’s Tandem Diabetes Care TNDM Stock Holding History

Eminence Capital’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,170,451	Closed	-$153M	–	70
2023 Q4	$153M	Sell	5,170,451 -319,566	-6%	-$6.63M	2.3%	13
2023 Q3	$114M	Buy	5,490,017 +2,372,458	+76%	+$65.2M	2.25%	17
2023 Q2	$76.5M	Buy	3,117,559 +647,902	+26%	+$20.8M	1%	40
2023 Q1	$100M	Sell	2,469,657 -313,816	-11%	-$13M	1.42%	29
2022 Q4	$125M	Buy	2,783,473 +1,192,686	+75%	+$54M	2.32%	10
2022 Q3	$76.1M	Buy	+1,590,787	New	+$87.2M	1.59%	25

Other funds holding TNDM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Eminence Capital's TNDM Position: Q1 2024 in Review

Eminence Capital sold out of Tandem Diabetes Care (TNDM) in Q1 2024, closing a stake of 5,170,451 shares — an estimated $153M sold.

Eminence Capital first reported a position in TNDM in Q3 2022 and held it in 6 quarters. The position peaked at $153M in Q4 2023. 291 funds tracked by Wall St. Rank hold TNDM as of Q1 2024.

Eminence Capital reported no remaining Tandem Diabetes Care position as of Q1 2024 after selling out during the quarter.
Eminence Capital sold 5,170,451 Tandem Diabetes Care shares in Q1 2024, an estimated $153M.
Eminence Capital first reported a position in Tandem Diabetes Care in Q3 2022 and held it in 6 quarters.
Eminence Capital's Tandem Diabetes Care position peaked at $153M in Q4 2023.
291 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2024.

Based on Eminence Capital's 13F filing for Q1 2024, filed 15 May 2024.